ACTRN12611000134921尚未招募未知
A 10 patient pilot study of bevacizumab (100-300mg) delivered by intraperitoneal infusion, to prevent or delay the recurrence of malignant ascites
Palliative Care Research Fund0 个研究点目标入组 10 人开始时间: 2011年2月4日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Participants must: be at least 18 years of age, have ascites in the setting of documented intra-abdominal malignant disease, have symptoms related to ascites that necessitate paracentesis for symptom control, be English speaking or have an interpreter available, be able to understand and comply with all trial requirements and the implications of off-label use of intraperitoneal bevacizumab, have exhausted all systemic chemotherapy options OR be unfit to receive systemic chemotherapy OR have declined systemic chemotherapy
排除标准
- •Patients will be excluded in the case of: ascites due to non-malignant cause, concurrent treatment with systemic chemotherapy that has a realistic chance of controlling the ascites, concurrent treatment with intravenous bevacizumab, life expectancy of less than 2 weeks, a history of bowel perforation or fistula, symptoms or signs suggestive of bacterial peritonitis, child c cirrhosis, uncontrolled hypertension, surgery within 28 days of treatment, evidence of coagulopathy, symptoms suggestive of bowel obstruction
研究者
相似试验
进行中（未招募）
1 期
Pilot study of bevacizumab as a treatment for respiratory distress in patients with COVID-19EUCTR2020-001541-39-ESFundación para la Investigación Biomédica de Córdoba22
招募中
不适用
A clinical study of Bevacizumab therapy in combination with chemotherapeutic drugs for children with recurrent gliomaJPRN-UMIN000005528Osaka University Graduate School of Medicine12
已完成
不适用
Monitoring of treatment with bevacizumab in patients with metastatic colorectal cancerCancerISRCTN59241668Institute Of Oncology Ljubljana (Slovenia)400
尚未招募
3 期
A study to compare bevacizumab drug in low dose versus standard dose in lung cancer patientsCTRI/2023/06/054174Tata Memorial Hospital
进行中（未招募）
不适用
Phase II clinical study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic breast cancerMetastatic or locally recurrent HER2-negative breast cancerMedDRA version: 12.0Level: LLTClassification code 10055113Term: Breast cancer metastaticMedDRA version: 12.0Level: LLTClassification code 10006198Term: Breast cancer recurrentEUCTR2009-016062-82-HUSOUTH EASTERN EUROPEAN RESEARCH ONCOLOGY GROUP88